Evidence map›Paper›PMID 42081171›Full record

Trial reportInvestigational new drugs2026

Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumors.

Alejandro Falcón, Gregory M Cote, Javier Molina-Cerrillo, Axel Le Cesne, Pedro Rocha, Bruno Bockorny, David Paez, Javier Martin-Broto, Sant P Chawla, Sara Martinez and 10 more

Registry-linked trialAbstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Investigational new drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02611024 (Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Pretreated Patients With Selected Advanced Solid Tumors), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02611024 phase1 / phase2completednot on this map

Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Pretreated Patients With Selected Advanced Solid Tumors

TypeinterventionalSponsorPharmaMarRan2016 to 2025Enrolled316ConditionsAdvanced Solid Tumors, Glioblastoma, Soft Tissue Sarcoma (Excluding GIST), Endometrial CarcinomaArmsLurbinectedin, Irinotecan
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Alejandro FalcónMedical Oncology Department, Hospital Universitario Virgen del Rocio, Seville, Spain. afalconglez@gmail.com.
Gregory M CoteMedical Oncology Department, Mass General Brigham Cancer Institute, Boston, MA, USA.
Javier Molina-CerrilloMedical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Axel Le CesneMedical Oncology Department, Institute Gustave Roussy, Villejuif, France.
Pedro RochaMedical Oncology Department, Vall d' Hebrón University Hospital, Barcelona, Spain.
Bruno BockornyMedical Oncology Department, Beth Israel Deaconess Medical Center, Boston, MA, USA.
David PaezMedical Oncology Department, Sant Pau, CIBERER, Hospital de La Santa Creu I, Barcelona, IRSANT PAU, Spain.
Javier Martin-BrotoMedical Oncology Department, Fundación Jiménez Díaz University Hospital General de Villalba, and Instituto deInvestigacion Sanitaria Fundacion Jimenez Diaz (IIS/FJDUAM), Madrid, Spain.
Sant P ChawlaSarcoma Oncology Research Center, Santa Monica, USA.
Sara MartinezClinical R&D, Pharma Mar, Colmenar Viejo, Madrid, Spain.
Carmen KahattClinical R&D, Pharma Mar, Colmenar Viejo, Madrid, Spain.
Vicente AlfaroClinical R&D, Pharma Mar, Colmenar Viejo, Madrid, Spain.
Mariano SigueroClinical R&D, Pharma Mar, Colmenar Viejo, Madrid, Spain.
Javier JimenezClinical R&D, Pharma Mar, Colmenar Viejo, Madrid, Spain.
Ana CustodioMedical Oncology Department, Hospital Universitario La Paz, Madrid, Spain.
Vicente Alonso-OrduñaMedical Oncology Department, Hospital Universitario Miguel Servet, Saragossa, Spain.
Carlos LópezMedical Oncology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL, UNICAN, Santander, Spain.
Attila KollárDepartment of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Juan José Soto-CastilloMedical Oncology Department, START Madrid CIOCC, Hospital Universitario HM Sanchinarro, Madrid, Spain.
Luis Paz-AresMedical Oncology Department, Hospital Universitario, 12 de Octubre, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lurbinectedin in combination with irinotecan showed synergistic antitumor activity in preclinical studies. A phase I/II trial (NCT02611024) evaluated this combination in patients with advanced solid tumors. The phase II stage evaluated the antitumor activity of the recommended dose (RD) (lurbinectedin 2.0 mg/m

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarbolinesHeterocyclic Compounds, 4 or More RingsIrinotecanNeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedYoung AdultCarbolinesHeterocyclic Compounds, 4 or More RingsIrinotecanPM 01183IrinotecanLurbinectedinPhase IPhase IIPooled safety

Identifiers

PMID42081171
PMCPMC13486034

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.